Drugs for Soft-Tissue Sarcoma
Here are the drugs and financial support services available to patients receiving treatment for Soft-Tissue Sarcoma.
Drug company: Eli Lilly
Lartruvo is a PDGFR-α inhibitor used, in combination with doxorubicin, for the treatment of patients with soft-tissue sarcoma.
Lilly PatientOne offers 2 financial assistance programs for patients using Lartruvo:
The Lilly PatientOne Co-pay Program
For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Lartruvo.
Lilly Cares Foundation Patient Assistance Program
For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and a household income up to 500% or less of the federal poverty level, this program provides Lartruvo at no cost.
Drug company: Novartis
Votrient is a kinase inhibitor used for the treatment of patients with advanced soft-tissue sarcoma.
Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Votrient:
Novartis Oncology Universal Co-pay Program
Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance. The program pays the remaining balance until a yearly maximum of $15,000 is met.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Votrient for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Votrient for free until a prescription drug coverage becomes available to them.
Drug company: Janssen
Yondelis is an alkylating drug used for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma (each of these is a rare type of soft-tissue sarcoma).
Janssen offers 2 financial assistance programs for patients using Yondelis:
Janssen CarePath Savings Program
With this program, privately insured patients may pay only $20 per infusion, with a maximum yearly benefit of $15,000.
Johnson & Johnson Patient Assistance Foundation
This program provides Yondelis free of cost to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.
Table. Drugs Prescribed for Soft-Tissue Sarcoma
- Drug name (generic name)
- Drug company
- Patient support services
Last modified: March 7, 2019